-
-
-
City, State:
Headquartered New York, NY (founded: Bucharest, Romania)
-
Finland, Institutional
ChangeCompany overview
UiPath aims to use the transformative power of automation to liberate the boundless potential of people—and drive profitable growth for enterprises. The AI-powered UiPath Business Automation Platform combines leading robotic process automation (RPA) with a full suite of capabilities to understand, automate, and operate end-to-end processes, offering unprecedented time to value.
Investment thesis
At the time of our investment in April 2019, we viewed robotic process automation as one of the fastest growing segments of the software market. We recognized UiPath as a leader in the category and believed in their ability to maintain tremendous adoption and growth to capture a meaningful portion of the multi-billion-dollar segment.
Wellington was a strategic pre-IPO partner for UiPath as we transitioned from the private to the public markets. They bring an extensive knowledge base and a broad network of relationships that was very helpful for us in the IPO process.
Daniel Dines is the CEO of UiPath, which is a portfolio company that Wellington has invested in. This statement about Wellington reflects a personal opinion that may not be shared by others. There has been no compensation provided for such statements.
We were thrilled to partner with UiPath's visionary management team and believed their cutting-edge technology harnessing AI to automate digital tasks to be industry leading.
Meet the late-stage growth team
- Co-Head, Private Investments
- Boston
- Sector Lead, Consumer
- San Francisco
- Sector Lead, Technology
- North Carolina
- Principal, Late-stage growth
- New York
- Principal, Late-stage growth
- Boston
- Sector Lead, Asia
- Singapore
- Sector Lead, Health Care
- Boston
- Head of Late-Stage Growth
- Denver
Our Focus Areas
Venture capital
From energy transformation to sustainable cities to next-generation agriculture, we support innovative companies helping to address the impacts of climate change.
We seek out companies at the nexus of scientific breakthroughs and medical needs with innovations that are improving the standard of care of medicine for patients.
To guide late-stage private companies through the finish line and beyond, we leverage our deep industry expertise, resources, and long-term relationships across public and private markets.
Private credit
